Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency.

Authors

Nelly Mauras, Yulia Skorodok, Violeta Iotova, Ron Rosenfeld, Michael P Wajnrajch, Oleg Malievskiy, Nataliya Zelinska, Srinivas Rao Valluri, Zvi Zadik

Published in

The Journal of clinical endocrinology and metabolism. Jun 29, 2026. Epub Jun 29, 2026.

Abstract

: Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD.
: Assess the long-term safety and efficacy of somatrogon in children with GHD.
: Open-label extension (OLE) study following an initial 12-month open-label phase 2 study.
: Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US.
: Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE.
: Participants received once-weekly somatrogon for up to 9 years.
: Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation.
Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed.
Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.

PMID:
42372104
Bibliographic data and abstract were imported from PubMed on 30 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.